Michelle I. Savage

TL;DR: There are four stable TNBC subtypes characterized by the expression of distinct molecular profiles that have distinct prognoses, and novel subtype-specific targets that can be targeted in the future for the effective treatment of TNBCs are identified.

TL;DR: Current research is focused on identifying preventive therapies for other forms of breast cancer such as human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC, breast cancer that does express ER, progesterone receptor, or HER2).

TL;DR: Both types of PTPs are discussed: those that have tumor suppressor activities as well as those that act as oncogenes, which positively regulate signaling pathways and promote tumor development and progression.

TL;DR: It is demonstrated that SOX11 is a critical regulator of multiple BLBC phenotypes, including growth, migration, invasion, and expression of signature BLBC genes.

TL;DR: Strategies targeting p53 mutants are reviewed, with focus on targeting the mutant p53 protein directly, and on the progress of identifying genes and pathways required in p53-mutant cells.